The specialist cancer drug discovery and development business has announced that its partner, the CRT Pioneer Fund, intends to complete the clinical trial application for the company’s lead oncology candidate CHK1 in January 2016. This suggests that the team has achieved the comfort it requires from preclinical work to proceed. As such this has triggered Sareum’s initial financial contribution to the Phase I trials; £797,500 will be paid this month from existing resources. W
